netFormulary NHS
North Staffordshire Joint Formulary
North Staffordshire Clinical Commissioning Group
Stoke-on-Trent Clinical Commissioning Group
 Search
 Formulary Chapter 2: Cardiovascular system - Full Chapter
02.03.02  Expand sub section  Drugs for arrhythmias
02.03.02  Expand sub section  Supraventricular arrhythmias
02.03.02  Expand sub section  Supraventricular and ventricular arrhythmias
Mexiletine 
(See prescribing restrictions)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
NHS England

Licensed preparation: Namuscla® 167mg hard capsules is reserved for non-dystrophic myotonia and it is not licensed for ventricular arrhythmia. This is an NHS England specialised commissioning medicine.

unlicensed Unlicensed preparation: Mexiletine 50mg, 100mg and 200mg capsules are unlicensed and only available from ’special-order’ manufacturers or specialist importing companies. For treatment of life-threatening ventricular arrhythmias (using the unlicensed preparations ONLY).

Restriction: Initiation under direction of cardiologist for VT

APC decision (August 2019): RAG rating change- reclassified as a Red drug (secondary care prescribing only).

 
   
Amiodarone Hydrochloride

View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Amiodarone Hydrochloride Tablet 100mg
Amiodarone Hydrochloride Tablet 200mg

Restriction: Initiation under direction of cardiologist

Beware of potential problems and recognise who is responsible for spotting them e.g. Micro-corneal deposits, Photosensitivity, Thyroid, Liver and Lung Disorders (check every 6 months).

MHRA/CHM advice: Sofosbuvir with daclatasvir; sofosbuvir and ledipasvir (May 2015); simeprevir with sofosbuvir (August 2015): risk of severe bradycardia and heart block when taken with amiodarone

NICE CG180 (Atrial fibrillation): Do not offer amiodarone for long-term rate control.

NHS England has identified this product as an item that should not be routinely prescribed in primary care (Ver. 2, June 2019)

NHS England: Items which should not be routinely prescribed in primary care: Guidance for CCGs

 
   
Disopyramide 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Disopyramide Capsule 100mg
Disopyramide Capsule 150mg 

Restriction: Initiation by cardiologist only

 
   
Flecainide Acetate 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Flecainide Acetate Tablet 50mg
Flecainide Acetate Tablet 100mg

Restriction: Initiation under direction of cardiologist

 
   
Propafenone Hydrochloride

View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Propafenone Hydrochloride Tablet 150mg 
Propafenone Hydrochloride Tablet 300mg

Restriction: Initiation under direction of cardiologist

 
   
Quinidine 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Quinidine 200mg tablets
Quinidine 300mg tablets
Quinidine 250mg SR tablets

Restriction: Initiation under direction of cardiologist

 
   
Sotalol Hydrochloride

View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Sotalol Hydrochloride Tablet 40mg
Sotalol Hydrochloride Tablet 80mg
Sotalol Hydrochloride Tablet 160mg

Restriction: Initiation under direction of cardiologist

 
   
Verapamil Hydrochloride

View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Verapamil Hydrochloride Capsule 120mg M/R
Verapamil Hydrochloride Capsule 180mg M/R
Verapamil HydrochlorideCapsule 240mg M/R
Verapamil Hydrochloride Tablet 40mg
Verapamil Hydrochloride Tablet 80mg
Verapamil Hydrochloride Tablet 120mg
Verapamil HydrochlorideTablet 120mg M/R- Prescribe brand
Verapamil Hydrochloride Tablet 160mg
Verapamil Hydrochloride Tablet 240mg M/R- Prescribe brand

Restriction: Initiation under direction of cardiologist

 
   
Adenosine 
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red

6mg/2mL Solution for Injection vials
30mg/10mL Solution for Infusion vials

Restriction: Anaesthetics and cardiology only

 
   
Lidocaine Hydrochloride

View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red

Solution for Injection vials

Restriction: Initiation under direction of cardiologist

 
   
02.03.02  Expand sub section  Ventricular arrhythmias
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG
Blueteq
High Cost Drug Approval System

Traffic Light Status Information

Status Description

Red

Medicines that can only be prescribed within Secondary Care. Examples of medicines which fall into this category are: Certain new medicines and new indications for older medicines where there is at present no experience of use in Primary Care. Medicines or dressings not available or prescribable in Primary Care. Where a medicine has been classified as Amber E, but an approved shared-care guideline is not yet available   

Amber

Medicines which can be prescribed within Secondary Care, but are only suitable for prescribing in Primary Care after specialist referral. There is no need for approved shared care guidelines for medicines in this category. This replaces Amber 2 on the North Staffs Formulary.   

Amber E

Medicines which can be prescribed within Secondary Care, but are only considered suitable for prescribing in Primary Care under an approved shared-care agreement (ESCA) or Rationale for Initiation, Continuation and Discontinuation (RICaD). This replaces Amber 1 on the North Staffs Formulary  

Green

Medicines which can be prescribed in either Primary or Secondary Care.  

Grey

These medicines have been reviewed by the New Medicines Committee and the Area Prescribing Committee and found not to be suitable for inclusion in the Joint Formulary. Inadequate or weak evidence for efficacy No clearly defined local need Lack of long term safety data No perceived benefit over established formulary alternatives Prescribers can consider these medicines where formulary alternatives are unsuitable, ineffective or not tolerated.  

netFormulary